UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 869

Sortiert nach

Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)

British journal of dermatology (1951), 2021-03, Vol.184 (3), p.437-449

2021

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of risankizumab vs. secukinumab in patients with moderate‐to‐severe plaque psoriasis (IMMerge): results from a phase III, randomized, open‐label, efficacy–assessor‐blinded clinical trial

British journal of dermatology (1951), 2021-01, Vol.184 (1), p.50-59

2021

Link zum Volltext

Verfügbarkeit prüfen

Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial

British journal of dermatology (1951), 2016-11, Vol.175 (5), p.902-911

2016

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)

British journal of dermatology (1951), 2015-12, Vol.173 (6), p.1387-1399

2015

Link zum Volltext

Verfügbarkeit prüfen

Distance of Hi-GAL sources

Astronomy and astrophysics (Berlin), 2021-02, Vol.646, p.A74

2021

Link zum Volltext

Verfügbarkeit prüfen

The Milky Way rotation curve revisited

Astronomy and astrophysics (Berlin), 2017-05, Vol.601, p.L5

2017

Link zum Volltext

Verfügbarkeit prüfen

Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up

British journal of dermatology (1951), 2015-05, Vol.172 (5), p.1371-1383

2015

Link zum Volltext

Verfügbarkeit prüfen

Early relapse of psoriasis after stopping brodalumab: a retrospective cohort study in 77 patients

Journal of the European Academy of Dermatology and Venereology, 2017-09, Vol.31 (9), p.1491-1496

2017

Link zum Volltext

Verfügbarkeit prüfen

Disease activity and treatment efficacy using patient-level Psoriasis Area and Severity Index scores from tildrakizumab phase 3 clinical trials

The Journal of dermatological treatment, 2022-01, Vol.33 (1), p.219-228

2022

Link zum Volltext

Verfügbarkeit prüfen

Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis: results from PHOENIX 1

British journal of dermatology (1951), 2014-02, Vol.170 (2), p.398-407

2014

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of tildrakizumab by patient demographic and disease characteristics across a phase 2b and 2 phase 3 trials in patients with moderate‐to‐severe chronic plaque psoriasis

Journal of the European Academy of Dermatology and Venereology, 2020-07, Vol.34 (7), p.1500-1509

2020

Link zum Volltext

Verfügbarkeit prüfen

Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis

Journal of the European Academy of Dermatology and Venereology, 2017-06, Vol.31 (6), p.1004-1013

2017

Link zum Volltext

Verfügbarkeit prüfen

Long‐term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3‐year results from two randomized phase III trials (CIMPASI‐1 and CIMPASI‐2)

British journal of dermatology (1951), 2021-04, Vol.184 (4), p.652-662

2021

Link zum Volltext

Verfügbarkeit prüfen

Adalimumab for nail psoriasis: efficacy and safety over 52 weeks from a phase‐3, randomized, placebo‐controlled trial

Journal of the European Academy of Dermatology and Venereology, 2019-11, Vol.33 (11), p.2168-2178

2019

Link zum Volltext

Verfügbarkeit prüfen

Long-term outcomes of interruption and retreatment vs. continuous therapy with adalimumab for psoriasis: subanalysis of REVEAL and the open-label extension study

Journal of the European Academy of Dermatology and Venereology, 2013-05, Vol.27 (5), p.634-642

2013

Link zum Volltext

Verfügbarkeit prüfen

Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient‐reported outcomes in the treatment of moderate to severe psoriasis: results of two phase III randomized, controlled trials

Journal of the European Academy of Dermatology and Venereology, 2017-03, Vol.31 (3), p.498-506

2017

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of follow-up field treatment of actinic keratosis with ingenol mebutate 0·015% gel: a randomized, controlled 12-month study

British journal of dermatology (1951), 2016-03, Vol.174 (3), p.505-513

2016

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of topical WBI-1001 in patients with mild to severe atopic dermatitis: results from a 12-week, multicentre, randomized, placebo-controlled double-blind trial

British journal of dermatology (1951), 2012-04, Vol.166 (4), p.853-860

2012

Link zum Volltext

Verfügbarkeit prüfen

Apremilast for the treatment of moderate‐to‐severe palmoplantar psoriasis: results from a double‐blind, placebo‐controlled, randomized study

Journal of the European Academy of Dermatology and Venereology, 2018-03, Vol.32 (3), p.403-410

2018

Link zum Volltext

Verfügbarkeit prüfen

Disease characteristics in patients with and without psoriatic arthritis treated with etanercept

Journal of the European Academy of Dermatology and Venereology, 2014-05, Vol.28 (5), p.581-589

2014

Link zum Volltext

Verfügbarkeit prüfen

Position statement for a pragmatic approach to immunotherapeutics in patients with inflammatory skin diseases during the coronavirus disease 2019 pandemic and beyond

Journal of the European Academy of Dermatology and Venereology, 2021-04, Vol.35 (4), p.797-806

2021

Link zum Volltext

Verfügbarkeit prüfen

Treatment of palmoplantar psoriasis with infliximab: a randomized, double-blind placebo-controlled study

Journal of the European Academy of Dermatology and Venereology, 2011-12, Vol.25 (12), p.1402-1408

2011

Link zum Volltext

Verfügbarkeit prüfen

Impact of ixekizumab on facial psoriasis and related quality of life measures in moderate‐to‐severe psoriasis patients: 12‐week results from two phase III trials

Journal of the European Academy of Dermatology and Venereology, 2018-01, Vol.32 (1), p.68-72

2018

Link zum Volltext

Verfügbarkeit prüfen

A 6-month maintenance therapy with adapalene-benzoyl peroxide gel prevents relapse and continuously improves efficacy among patients with severe acne vulgaris: results of a randomized controlled trial

British journal of dermatology (1951), 2011-06, Vol.164 (6), p.1376-1382

2011

Link zum Volltext

Verfügbarkeit prüfen

A Randomized, blinded assessor study to Evaluate the efFIcacy and safety of etanercept 50 mg once weekly plus as Needed topical agent vs. Etanercept 50 mg twice weekly in patients with moderate to severe plaque psoriasis (REFINE)

Journal of the European Academy of Dermatology and Venereology, 2015-02, Vol.29 (2), p.361-366

2015

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 869

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(572)
Mit Volltextzugriff
(775)

Publikationsform

5 weitere anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(212)
Life Sciences & Biomedicine
(178)
Humans
(164)
Female
(101)
Biological And Medical Sciences
(92)
Male
(80)
Medical Sciences
(67)
Dermatology
(63)
Middle Aged
(57)
Adult
(52)
Animals
(50)
Treatment Outcome
(45)
Psoriasis - Drug Therapy
(40)
Physical Sciences
(34)
Aged
(32)
Double-Blind Method
(32)
Sciences Biologiques Et Medicales
(31)
Fundamental And Applied Biological Sciences. Psychology
(28)
Life Sciences
(28)
Severity Of Illness Index
(23)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)

Efficacy and safety of risankizumab vs. secukinumab in patients with moderate‐to‐severe plaque psoriasis (IMMerge): results from a phase III, randomized, open‐label, efficacy–assessor‐blinded clinical trial

Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial

Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)

Distance of Hi-GAL sources

The Milky Way rotation curve revisited

Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up

Early relapse of psoriasis after stopping brodalumab: a retrospective cohort study in 77 patients

Disease activity and treatment efficacy using patient-level Psoriasis Area and Severity Index scores from tildrakizumab phase 3 clinical trials

Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis: results from PHOENIX 1

Efficacy of tildrakizumab by patient demographic and disease characteristics across a phase 2b and 2 phase 3 trials in patients with moderate‐to‐severe chronic plaque psoriasis

Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis

Long‐term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3‐year results from two randomized phase III trials (CIMPASI‐1 and CIMPASI‐2)

Adalimumab for nail psoriasis: efficacy and safety over 52 weeks from a phase‐3, randomized, placebo‐controlled trial

Long-term outcomes of interruption and retreatment vs. continuous therapy with adalimumab for psoriasis: subanalysis of REVEAL and the open-label extension study

Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient‐reported outcomes in the treatment of moderate to severe psoriasis: results of two phase III randomized, controlled trials

Efficacy and safety of follow-up field treatment of actinic keratosis with ingenol mebutate 0·015% gel: a randomized, controlled 12-month study

Efficacy and safety of topical WBI-1001 in patients with mild to severe atopic dermatitis: results from a 12-week, multicentre, randomized, placebo-controlled double-blind trial

Apremilast for the treatment of moderate‐to‐severe palmoplantar psoriasis: results from a double‐blind, placebo‐controlled, randomized study

Disease characteristics in patients with and without psoriatic arthritis treated with etanercept

Position statement for a pragmatic approach to immunotherapeutics in patients with inflammatory skin diseases during the coronavirus disease 2019 pandemic and beyond

Treatment of palmoplantar psoriasis with infliximab: a randomized, double-blind placebo-controlled study

Impact of ixekizumab on facial psoriasis and related quality of life measures in moderate‐to‐severe psoriasis patients: 12‐week results from two phase III trials

A 6-month maintenance therapy with adapalene-benzoyl peroxide gel prevents relapse and continuously improves efficacy among patients with severe acne vulgaris: results of a randomized controlled trial

A Randomized, blinded assessor study to Evaluate the efFIcacy and safety of etanercept 50 mg once weekly plus as Needed topical agent vs. Etanercept 50 mg twice weekly in patients with moderate to severe plaque psoriasis (REFINE)

Suchergebnisse filtern